Selvita, one of the largest preclinical CROs in Europe, continued its growth strategy with the completion of its new headquarters in Krakow, Poland.
The 4,000-square-meter Selvita Research Center is part of the CRO’s strategy to bolster organic growth to cement its position, the company said in a March 27 press release.
The new space will house part of Selvita's drug discovery activities. That move will allow the company to expand operations in drug development and analytical testing at its current facilities nearby. The new location will also offer a range of drug discovery labs including medicinal chemistry, biochemistry, in vitro biology, ADME/DMPK and in vivo pharmacology.
“At Selvita, we understand that access to the state-of-the-art infrastructure and scientific technology platforms is crucial for the continued organic growth of a reliable and vibrant research organization aiming at scientific excellence,” Miroslawa Zydron, Selvita's chief operating officer, said in the release. “To guarantee this, we invested in construction of our own facility, ensuring that the labs we move into will be fully adapted to our needs and will contribute to the success of our partners' projects.”
Selvita currently operates in several locations, including Krakow; Poznan, Poland; and Zagreb, Croatia. The company snapped up the Croatia facility in 2020 as part of a $37 million deal to buy Fidelta, then a unit of drug developer Galapagos.